Hemlibra, Lynparza, Zejula Face Quarterly Re-Pricing, 7.7-10.2% Cut in November

Chuikyo General Assembly Meeting on August 23 Three drugs including Chugai Pharmaceutical’s hemophilia A drug Hemlibra (emicizumab) were newly caught by quarterly price reviews, facing reductions of 7.7-10.2% under market expansion re-pricing, effective November 1. The two other drugs to...read more